Barnard Zachary R, Drazin Doniel, Bannykh Serguei I, Rudnick Jeremy D, Chu Ray M
Neurosurgery, Cedars-Sinai Medical Center.
Pathology, Cedars-Sinai Medical Center.
Cureus. 2015 Dec 25;7(12):e434. doi: 10.7759/cureus.434.
Adult, malignant brainstem gliomas are rare entities that often cause treatment conundrums due to the difficulty of surgical resection and, therefore, the absence of pathological diagnosis. This leads to a reliance on radiological imaging for diagnosis, which can often be unreliable. These shortcomings have made the treatment of brainstem gliomas challenging with unpredictable outcomes. The mainstay of treatment consists of chemotherapy and radiation; however, recurrence is inevitable. Predicting outcomes has been the major difficulty in treating these patients as adult malignant brainstem gliomas Grade II have a median survival between five to seven years while Grades III and IV are between 10-17 months (with some studies showing significantly longer survival in Grade III). Here, we present the case of a patient with the pathologic diagnosis of a right brachium pontis glioblastoma who had a remarkable survival of 73 months, whereas the expected median survival for these patients is 10-17 months.
成人恶性脑干胶质瘤是罕见的疾病，由于手术切除困难，因此缺乏病理诊断，常常导致治疗难题。这导致依赖放射影像学进行诊断，而放射影像学诊断往往不可靠。这些缺点使得脑干胶质瘤的治疗具有挑战性，预后难以预测。治疗的主要方法包括化疗和放疗；然而，复发是不可避免的。预测预后一直是治疗这些患者的主要困难，因为成人恶性二级脑干胶质瘤的中位生存期为五至七年，而三级和四级则为10 - 17个月（一些研究表明三级患者的生存期明显更长）。在此，我们报告一例经病理诊断为右侧脑桥臂胶质母细胞瘤的患者，其生存期长达73个月，显著长于这些患者预期的中位生存期10 - 17个月。
